GleamWall
中文EN

BLGO BIOLARGO, INC.

Chemicals & Allied Products · OTC · SEC CIK 880242 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-62.3%
TTM net income YoY-7.8%
TTM EPS YoY—
Revenue 3-yr CAGR-25.8%
Net income 3-yr CAGR—

Margins

Gross margin43.7%
Operating margin-355.4%
Net margin-260.6%
FCF margin—
EBITDA margin-349.9%

Returns

ROE-1,608.5%
ROA-129.8%
ROIC (approx.)—
Asset turnover0.50x

Leverage & solvency

Liabilities / assets165.9%
Debt / equity—
Current ratio0.60x
Interest coverage-14.79x

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$1.09M$1.25M$1.11M$617,000$1.10M$2.78M$3.27M$3.66M
Cost of revenue$574,000$573,000$657,000$489,000$731,000$1.36M$1.78M$1.91M
Gross profit$516,000$675,000$458,000$128,000$372,000$1.42M$1.49M$1.75M
R&D expense$810,000$1.09M$907,000$659,000$615,000$535,000$791,000$784,000
SG&A expense$3.23M$3.31M$2.75M$3.43M$3.09M$2.69M$2.52M$2.58M
Operating income-$3.52M-$3.73M-$3.20M-$4.01M-$7.18M-$1.80M-$1.86M-$1.62M
Interest expense$317,000$285,000$188,000$188,000$144,000$115,000$93,000$32,000
Net income-$2.60M-$2.77M-$2.29M-$2.95M-$6.48M-$1.19M-$1.16M-$1.01M
EBITDA-$3.39M-$3.70M-$3.17M-$3.98M-$7.15M-$1.77M-$1.82M-$1.58M
EPS (basic)-0.01-0.01-0.01—-0.02-0.000.00—
EPS (diluted)————————
Banking
Net interest income-$302,000-$272,000-$116,000$12,000-$64,000-$80,000-$65,000-$21,000
Balance sheet
Cash & equivalents$1.53M$2.19M$4.12M$3.88M$4.55M$3.47M$2.56M$3.55M
Receivables$1.42M$724,000$730,000$615,000$761,000$1.74M$4.21M$3.17M
Inventory$322,000$303,000$292,000$310,000$409,000$444,000$369,000$330,000
Current assets$3.54M$3.50M$5.45M$5.11M$5.78M$9.19M$7.22M$7.14M
PP&E, net$1.68M$1.77M$1.64M$1.64M$1.66M$1.66M$1.70M$1.74M
Total assets$7.21M$6.67M$8.56M$8.31M$9.13M$12.50M$10.51M$10.51M
Current liabilities$5.94M$4.76M$4.93M$5.06M$3.45M$4.08M$3.37M$2.65M
Short-term debt————$83,000$83,000—$66,000
Long-term debt———$2.08M———$1.08M
Total debt———$2.08M———$1.15M
Total liabilities$11.96M$9.40M$8.75M$6.79M$5.92M$6.44M$5.42M$4.46M
Shareholders' equity-$5.26M-$1.85M$1.79M$4.04M$6.58M$8.76M$7.61M$8.85M
Net debt———-$1.80M———-$2.40M
Cash flow statement
Operating cash flow-$2.21M-$3.06M-$2.92M-$1.59M-$2.76M-$2.12M-$1.83M-$1.92M
Investing cash flow-$43,000-$160,000-$32,000-$13,000$256,000$192,000$0-$57,000
Financing cash flow$1.61M$1.28M$3.19M$952,000$3.57M$2.83M$866,000$1.59M
Depreciation & amortization$128,000$31,000$34,000$33,000$34,000$36,000$42,000$40,000
Stock-based compensation$827,000$722,000$699,000$1.01M$844,000$492,000$615,000$799,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.